Bloomage BioTechnology formed a JV with South Korea's Medytox to market Medytox's version of the wrinkle treatment Botox (Botulinum Toxin) in China. The JV, which will be owned 50-50 by the two partners, will be called Medybloom. Bloomage is already involved in China's aesthetic care market as a producer of hyaluronic acid. It markets various grades of HA in China as orthopedic injections, ophthalmic solutions, cosmetic fillers, surgical anti-adhesion products and food supplements.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
